Alingsas

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3, randomized, placebo-controlled study. This trial focuses on patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study aims to assess how AZD0780 compares to placebo in reducing the risk of major adverse cardiovascular events, also known as MACE-PLUS, over the course of the trial. Participants are randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study continues until a primary analysis censoring date, which may be up to approximately 54 months from randomization. After this, a study closure visit will be conducted as the final visit for each participant. During the study, participants will be regularly monitored for cardiovascular events including heart attacks, strokes, urgent coronary revascularizations, and other related outcomes. Researchers will track the time to first occurrence of these events as the primary outcome. Safety and other secondary outcomes like all-cause mortality will also be assessed. The total participation time can last up to about 54 months, with ongoing evaluations throughout this period.

Researchers are evaluating oral icotrokinra as a treatment for adults and adolescents with moderately to severely active ulcerative colitis, a chronic inflammatory disease of the large intestine causing ulcers in the colon lining. The study aims to assess how well icotrokinra works, along with its safety and tolerability in this population. This is a Phase 3, randomized, double-blind, placebo-controlled trial with a parallel group design including both adults and adolescents. Adult participants will be randomly assigned to receive either icotrokinra or placebo daily by mouth during a 12-week induction phase. At Week 12, those showing clinical response will enter a maintenance phase where they will continue icotrokinra or placebo daily for 40 weeks. Adults who do not respond will also enter the maintenance phase and receive icotrokinra. Adolescents will receive open-label icotrokinra during induction and then continue on icotrokinra during maintenance regardless of response. After completing the 40-week maintenance phase, eligible participants may join a long-term extension study. Participants will be monitored regularly through clinical assessments at specified time points including Week 12 for induction and Week 40 for maintenance. Outcomes measured include rates of clinical remission, symptom improvement, endoscopic and histologic healing, and quality of life scores. Safety will be evaluated by tracking adverse and serious adverse events throughout the study. The total study duration may extend up to approximately 6 years, ending in 2032, allowing long-term evaluation of icotrokinra in ulcerative colitis management.

Researchers are evaluating icotrokinra for its effectiveness and safety in people with moderately to severely active Crohns disease, a condition causing severe inflammation in the intestines. This clinical trial is a Phase 2b3 study aiming to understand how well icotrokinra works compared to placebo to improve symptoms and intestinal healing. Participants will be randomly assigned to receive one of several treatments two different doses of icotrokinra or a matching placebo, taken orally every day during an induction period of up to 12 weeks. Based on their response at Week 12, participants may continue with maintenance dosing or placebo up to Week 40. Those completing the maintenance phase may join a long-term extension study for further evaluation. During the trial, participants will be monitored with clinical assessments, endoscopy, and patient-reported outcomes to measure response, remission, and safety. The main outcomes include clinical response and remission at Weeks 12 and 40, along with endoscopic healing. Safety will be tracked through adverse event reporting up to four weeks after the last dose. The study is expected to continue until 2032, with multiple visits for treatment and evaluations throughout.

Researchers are studying patients who experience out-of-hospital cardiac arrest OHCA with ventricular fibrillation VF or ventricular tachycardia VT that do not respond to initial defibrillation. The study aims to evaluate whether using double sequential defibrillation DSD earlier, after the first failed standard defibrillation, can improve 30-day survival compared to continuing with standard defibrillation. This trial addresses important gaps in knowledge about optimal defibrillation strategies to increase survival in this critical condition. The trial compares two treatment groups one using early double sequential defibrillation, where a second defibrillator with pads placed in the anterior-posterior position is applied as soon as possible, delivering rapid sequential shocks from two devices and the other continuing with standard single defibrillation using one defibrillator with anterior-lateral pad placement. Both groups receive resuscitation until return of spontaneous circulation, resuscitation is stopped, or the patient is transported to the hospital. The study is randomized and open-label, involving ambulance units equipped with two study-specific defibrillators. Participants are adult OHCA patients with an initial shockable rhythm and at least one failed standard defibrillation. During the study, ambulance teams perform screening, randomization, treatment according to assigned group, and initial follow-up. The main outcome measured is survival at 30 days. Secondary outcomes include return of spontaneous circulation, survival to hospital admission and discharge, and neurological function at discharge. The study will continue monitoring these outcomes to assess the effectiveness of early DSD compared to standard defibrillation strategies.

Aortic valve stenosis AS is the most common valve disease in older adults and often leads to high mortality if symptomatic. The main treatment improving survival is transcatheter aortic valve implantation TAVI, which allows many frail older patients with comorbidities to receive valve intervention. This study evaluates whether physiotherapist-led exercise-based cardiac rehabilitation PT-X after TAVI can improve physical fitness, physical activity, and health-related quality of life HR-QoL, while also examining frailty prevalence and hospital admissions during the first year after TAVI. Participants in the PT-X group will follow an individualized exercise program at a hospital-based setting, including central circulatory aerobic and muscular endurance training twice weekly for 60 minutes over 12 weeks, plus two home sessions tracked in an exercise diary. The control group will continue with their usual activities without this specific intervention. Exercise intensity is guided by perceived exertion on Borgs scale. The study compares the effects of PT-X versus no intervention on physical capacity and quality of life after TAVI. During the study, researchers will assess exercise capacity through tests measuring work capacity in watts, muscular endurance, physical activity levels, and HR-QoL at baseline, after 12 weeks, and at 12 months post-intervention. Frailty status and hospital admission rates will also be monitored over this time. These evaluations aim to understand how PT-X influences recovery and long-term health outcomes in older adults treated with TAVI.

This research aims to determine if hip replacement surgery arthroplasty can reduce the need for additional operations compared to internal fixation in elderly patients with an undisplaced femoral neck fracture. Patients aged 75 years and older with this type of fracture will be included and randomly assigned to one of two treatments through the Swedish Fracture Register platform. The study focuses on combining reoperation rates and mortality into a single main outcome measure to evaluate which treatment offers better results. Participants will receive either arthroplasty, which may be hemi or total hip replacement depending on the patients condition and surgeons decision, or internal fixation using screws, pins, or a sliding hip screw device based on hospital routine. The study is a randomized controlled trial without blinding, comparing these two device-based treatments for hip fractures in elderly patients. During the study, researchers will monitor the combined rate of reoperations and mortality for 1 to 2 years after surgery. Additional outcomes include reoperation rates, short- and long-term mortality, and patient-reported physical function one year after surgery. Participants will be followed up to assess these outcomes, with care taken to track their progress and safety over the study period.

Children with functional constipation often experience physical and psychological difficulties that impact both them and their families. Many children seek care at primary healthcare centers, pediatric clinics, and emergency departments due to constipation symptoms. While medical treatment and dietary advice are provided, there is limited support from healthcare services, and physiotherapists are not typically involved in their care. Regular physical activity is recommended but lacks scientific evidence as a treatment for this condition. This study aims to explore parents experiences of their childrens physical activity to better understand its role in managing functional constipation. The study involves interviewing parents of children aged 6 to 12 years with functional constipation who are receiving treatment at pediatric clinics. The method used is semi-structured, in-depth individual interviews, which will be transcribed and analyzed to capture both explicit and underlying messages. The research is observational and qualitative, focusing on gathering new knowledge about physical activity in children with functional constipation. Participants will be involved through interviews conducted between November 2025 and April 2026. The researchers will explore parents perspectives on physical activity and how it relates to their childrens condition. The findings aim to fill a knowledge gap and may support future improvements in care, potentially involving physiotherapists as part of the treatment team. The total participation duration includes the interview process within the specified timeframe.

This research aims to study the recovery process in men undergoing surgery for benign prostatic hyperplasia BPH. It specifically looks at patient-reported outcomes such as pain, burning sensation, urine leakage, hematuria, and the use of pain-relieving medications during the first three months after surgery. The study will compare these outcomes across three different surgical techniques transurethral resection, transurethral vaporization, and GreenLight laser enucleation of the prostate Green-LEP. Patients undergoing any of the three surgical methods for BPH will be included in this prospective observational study. They will complete a daily self-assessment form for three months to record pain levels, burning sensation, urine leakage, use of painkillers, and hematuria. After this period, patients will be sent questionnaires to assess their urinary symptoms using the IPSS form at six months and then annually for up to five years, allowing for long-term follow-up of their recovery and symptom changes. Participants will be closely monitored through daily reports for three months and periodic questionnaires afterward. The study will use numeric rating scales for pain and burning, daily yesno questions for urine leakage and hematuria, and detailed medication logs. Researchers aim to understand the timeline and intensity of recovery symptoms, evaluate differences between surgical methods, and provide insights to improve patient care and counseling. The total observation period can be up to five years including annual follow-ups.

This observational study focuses on adults with distal radius fractures, the most common fracture type in Sweden. It aims to understand patients daily pain experience, hand function, and recovery over the first three months after injury. The study includes both patients treated with a cast and those who have undergone surgery, providing detailed patient-reported outcomes to better capture recovery and satisfaction. Participants are grouped into two categories those treated conservatively with a forearm cast and those who receive surgical treatment. Both groups will record daily pain levels, analgesic use, and weekly hand function using the Patient Reported Wrist Evaluation form. Additionally, data on the use and effectiveness of wrist splints, sick leave, and return to work will be collected through questionnaires without requiring extra clinic visits. During the three-month study period, patients will report their pain every day and hand function weekly via questionnaires. Researchers will also monitor analgesic use and wrist splint application weekly. The study relies entirely on patient-reported outcomes, so no additional physical appointments are needed. The primary measure is weekly hand function, with secondary measures including daily pain and medication use, aiming to provide a comprehensive view of recovery after distal radius fracture.

Researchers are evaluating the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients who have chronic heart failure, impaired kidney function, and have recently experienced a heart failure event. This Phase III study is conducted internationally across about 700 sites and aims to assess how these treatments impact cardiovascular death and heart failure events. Participants will be randomly assigned to one of three groups balcinrenonedapagliflozin 15 mg10 mg plus placebo, balcinrenonedapagliflozin 40 mg10 mg plus placebo, or dapagliflozin 10 mg plus placebo. Each participant will take one capsule and one tablet daily. The study duration averages 22 months, including screening, about 20 months of blinded treatment, and a one-month follow-up with open-label dapagliflozin. During the study, participants will undergo assessments for heart failure events, hospitalizations, and cardiovascular death. Researchers will monitor these outcomes over about 38 months, including symptom scores and other health measures. Safety and treatment effects will be followed during the treatment and the one-month post-treatment period.